New injection method aims to stop bladder cancer from returning

NCT ID NCT07198451

Not yet recruiting Disease control Sponsor: Shanghai University of Traditional Chinese Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether injecting the chemotherapy drug gemcitabine directly into the bladder wall can prevent cancer from coming back in people with intermediate- or high-risk non-muscle-invasive bladder cancer. About 320 participants will receive either the new injection or the standard treatment (a liquid instilled into the bladder). The goal is to see if the new method lowers the chance of recurrence over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine
What this could lead to: If it works, this could offer a more effective way to prevent bladder cancer from coming back, potentially reducing the need for repeated surgeries or stronger treatments.
What could go wrong: This is an early-phase trial (Phase 2/3) with only 320 participants, so results may not apply to everyone. The injection method is new and could have unknown risks or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.